pioglitazone has been researched along with Age-Related Memory Disorders in 22 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The present study was undertaken to investigate possible mechanism of pioglitazone-induced beneficial effect in memory deficits associated with experimental dementia." | 7.75 | Exploring mechanism of pioglitazone-induced memory restorative effect in experimental dementia. ( Jaggi, AS; Kaur, B; Singh, N, 2009) |
| "Pioglitazone is a peroxisome proliferator-activated receptor-γ (PPAR-γ) agonist and is widely used to treat type 2 diabetes." | 5.51 | Low-dose pioglitazone can ameliorate learning and memory impairment in a mouse model of dementia by increasing LRP1 expression in the hippocampus. ( Cha, BS; Kang, ES; Kim, E; Lee, BW; Lee, HC; Lee, M; Lee, PH; Lee, YH; Moon, JH; Seok, H; Shin, E; Yun, MR, 2019) |
| "Pioglitazone was given at the dose of 10mg/kgd by gavage for the last 12weeks of the 16-week period." | 5.36 | Effect of pioglitazone on insulin resistance in fructose-drinking rats correlates with AGEs/RAGE inhibition and block of NADPH oxidase and NF kappa B activation. ( Hao, Y; Hou, L; Liu, X; Luo, D; Zhang, S; Zheng, M, 2010) |
| "Accumulating evidence indicates that elevated levels of methionine are associated with cognitive decline, including loss of memory." | 4.12 | The Protective Effects of Pioglitazone Against Cognitive Impairment Caused by L-methionine Administration in a Rat Model. ( Al-Azzam, SI; Alfaqih, M; Alrabadi, N; Alzoubi, KH; Khabour, OF; Mhaidat, NM; Tashtoush, M, 2022) |
| "The present study was undertaken to investigate possible mechanism of pioglitazone-induced beneficial effect in memory deficits associated with experimental dementia." | 3.75 | Exploring mechanism of pioglitazone-induced memory restorative effect in experimental dementia. ( Jaggi, AS; Kaur, B; Singh, N, 2009) |
| "Patients diagnosed with fetal alcohol spectrum disorder (FASD) show persistent cognitive disabilities, including memory deficits." | 1.91 | The role of PPAR-γ in memory deficits induced by prenatal and lactation alcohol exposure in mice. ( de la Torre, R; Gallego-Landin, I; Garcia-Baos, A; Pastor, A; Sanz, F; Valverde, O, 2023) |
| "Treatment with fenofibrate, pioglitazone and their combination resulted in a significant improvement in the behavioural and neurochemical changes induced by βA injection." | 1.56 | Neuroprotective effect of PPAR alpha and gamma agonists in a mouse model of amyloidogenesis through modulation of the Wnt/beta catenin pathway via targeting alpha- and beta-secretases. ( Assaf, N; El Sayed, NS; El-Shamarka, ME; Khadrawy, YA; Salem, NA, 2020) |
| "Pioglitazone is a peroxisome proliferator-activated receptor-γ (PPAR-γ) agonist and is widely used to treat type 2 diabetes." | 1.51 | Low-dose pioglitazone can ameliorate learning and memory impairment in a mouse model of dementia by increasing LRP1 expression in the hippocampus. ( Cha, BS; Kang, ES; Kim, E; Lee, BW; Lee, HC; Lee, M; Lee, PH; Lee, YH; Moon, JH; Seok, H; Shin, E; Yun, MR, 2019) |
| "Insulin resistance is known to be a risk factor for cognitive impairment, most likely linked to insulin signaling, microglia overactivation, and beta amyloid (Aβ) deposition in the brain." | 1.43 | Pioglitazone and exenatide enhance cognition and downregulate hippocampal beta amyloid oligomer and microglia expression in insulin-resistant rats. ( Gad, ES; Moustafa, YM; Zaitone, SA, 2016) |
| " The current study was carried out to investigate the effects of chronic administration of pioglitazone, a PPAR-γ agonist, on cognitive impairment in an animal model of Alzheimer's disease induced by β-amyloid." | 1.40 | Role of nuclear receptor on regulation of BDNF and neuroinflammation in hippocampus of β-amyloid animal model of Alzheimer's disease. ( Kumar, A; Prakash, A, 2014) |
| "Pioglitazone ameliorates memory deficits in STZ-induced diabetic mice by reducing brain Aβ level via activation of PPARγ, which is independent of its effects on blood glucose and insulin levels." | 1.39 | Pioglitazone ameliorates memory deficits in streptozotocin-induced diabetic mice by reducing brain β-amyloid through PPARγ activation. ( Hong, H; Hu, M; Hu, W; Jiang, LY; Li, YQ; Liu, LP; Long, Y; Wang, C; Wang, JQ; Yan, TH; Zhang, Q, 2013) |
| "Pioglitazone was also investigated for its effects on parameters of oxidative stress by measuring malondialdehyde (MDA) and reduced glutathione (GSH) levels in the brain." | 1.38 | Improvement in long term and visuo-spatial memory following chronic pioglitazone in mouse model of Alzheimer's disease. ( Gupta, LK; Gupta, R, 2012) |
| "2) Treatment with pioglitazone significantly improved the memory performance in morphine-treated mice in both tests." | 1.38 | Involvement of nitric oxide in pioglitazone memory improvement in morphine-induced memory impaired mice. ( Almasi-Nasrabadi, M; Babaei, R; Dehpour, AR; Javadi-Paydar, M; Mahdavian, S; Norouzi, A; Sharifian, M, 2012) |
| "Pioglitazone was given at the dose of 10mg/kgd by gavage for the last 12weeks of the 16-week period." | 1.36 | Effect of pioglitazone on insulin resistance in fructose-drinking rats correlates with AGEs/RAGE inhibition and block of NADPH oxidase and NF kappa B activation. ( Hao, Y; Hou, L; Liu, X; Luo, D; Zhang, S; Zheng, M, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (9.09) | 29.6817 |
| 2010's | 17 (77.27) | 24.3611 |
| 2020's | 3 (13.64) | 2.80 |
| Authors | Studies |
|---|---|
| Garcia-Baos, A | 1 |
| Pastor, A | 1 |
| Gallego-Landin, I | 1 |
| de la Torre, R | 1 |
| Sanz, F | 1 |
| Valverde, O | 1 |
| Assaf, N | 1 |
| El-Shamarka, ME | 1 |
| Salem, NA | 1 |
| Khadrawy, YA | 1 |
| El Sayed, NS | 1 |
| Alzoubi, KH | 1 |
| Khabour, OF | 1 |
| Alfaqih, M | 1 |
| Tashtoush, M | 1 |
| Al-Azzam, SI | 1 |
| Mhaidat, NM | 1 |
| Alrabadi, N | 1 |
| Silva-Abreu, M | 1 |
| Calpena, AC | 1 |
| Andrés-Benito, P | 1 |
| Aso, E | 1 |
| Romero, IA | 1 |
| Roig-Carles, D | 1 |
| Gromnicova, R | 1 |
| Espina, M | 1 |
| Ferrer, I | 1 |
| García, ML | 1 |
| Male, D | 1 |
| Seok, H | 1 |
| Lee, M | 1 |
| Shin, E | 1 |
| Yun, MR | 1 |
| Lee, YH | 1 |
| Moon, JH | 1 |
| Kim, E | 1 |
| Lee, PH | 1 |
| Lee, BW | 1 |
| Kang, ES | 1 |
| Lee, HC | 1 |
| Cha, BS | 1 |
| Liu, LP | 2 |
| Yan, TH | 1 |
| Jiang, LY | 3 |
| Hu, W | 2 |
| Hu, M | 3 |
| Wang, C | 2 |
| Zhang, Q | 1 |
| Long, Y | 2 |
| Wang, JQ | 1 |
| Li, YQ | 1 |
| Hong, H | 3 |
| Prakash, A | 3 |
| Kumar, A | 3 |
| Ming, LC | 1 |
| Mani, V | 1 |
| Majeed, AB | 1 |
| Gad, ES | 1 |
| Zaitone, SA | 1 |
| Moustafa, YM | 1 |
| Kaur, B | 1 |
| Singh, N | 1 |
| Jaggi, AS | 1 |
| Liu, X | 1 |
| Luo, D | 1 |
| Zheng, M | 1 |
| Hao, Y | 1 |
| Hou, L | 1 |
| Zhang, S | 1 |
| Allami, N | 1 |
| Javadi-Paydar, M | 3 |
| Rayatnia, F | 1 |
| Sehhat, K | 1 |
| Rahimian, R | 1 |
| Norouzi, A | 3 |
| Dehpour, AR | 3 |
| Ponce-Lopez, T | 1 |
| Liy-Salmeron, G | 1 |
| Hong, E | 1 |
| Meneses, A | 1 |
| Xiang, GQ | 1 |
| Tang, SS | 2 |
| Li, Q | 1 |
| Wang, XY | 2 |
| Zhang, TT | 1 |
| Yin, L | 1 |
| Almasi-Nasrabadi, M | 2 |
| Mahdavian, S | 2 |
| Babaei, R | 2 |
| Sharifian, M | 2 |
| Gupta, R | 1 |
| Gupta, LK | 1 |
| Liao, MX | 1 |
| Ding, QL | 1 |
| Li, JC | 1 |
| Suge, R | 1 |
| Shimazu, T | 1 |
| Hasegawa, H | 1 |
| Inoue, I | 1 |
| Hayashibe, H | 1 |
| Nagasaka, H | 1 |
| Araki, N | 1 |
| Katayama, S | 1 |
| Nomura, M | 1 |
| Watanabe, S | 1 |
| Rahigude, A | 1 |
| Bhutada, P | 1 |
| Kaulaskar, S | 1 |
| Aswar, M | 1 |
| Otari, K | 1 |
| Pathan, AR | 1 |
| Viswanad, B | 1 |
| Sonkusare, SK | 1 |
| Ramarao, P | 1 |
22 other studies available for pioglitazone and Age-Related Memory Disorders
| Article | Year |
|---|---|
The role of PPAR-γ in memory deficits induced by prenatal and lactation alcohol exposure in mice.
Topics: Animals; Child; Female; Fetal Alcohol Spectrum Disorders; Humans; Lactation; Memory Disorders; Mice; | 2023 |
Neuroprotective effect of PPAR alpha and gamma agonists in a mouse model of amyloidogenesis through modulation of the Wnt/beta catenin pathway via targeting alpha- and beta-secretases.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Animals; Cognitive D | 2020 |
The Protective Effects of Pioglitazone Against Cognitive Impairment Caused by L-methionine Administration in a Rat Model.
Topics: Animals; Antioxidants; Cognitive Dysfunction; Hippocampus; Hypoglycemic Agents; Male; Maze Learning; | 2022 |
PPARγ agonist-loaded PLGA-PEG nanocarriers as a potential treatment for Alzheimer's disease: in vitro and in vivo studies.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Blood-Brain Barrier; Cells, Cultured; Di | 2018 |
Low-dose pioglitazone can ameliorate learning and memory impairment in a mouse model of dementia by increasing LRP1 expression in the hippocampus.
Topics: Amyloid beta-Peptides; Animals; Dementia; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; | 2019 |
Pioglitazone ameliorates memory deficits in streptozotocin-induced diabetic mice by reducing brain β-amyloid through PPARγ activation.
Topics: Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Amyloid Precursor Protein Secretases; Animals | 2013 |
Pioglitazone alleviates the mitochondrial apoptotic pathway and mito-oxidative damage in the d-galactose-induced mouse model.
Topics: Acetylcholinesterase; Aging; Animals; Antioxidants; Apoptosis; Behavior, Animal; Brain; Caspase 3; C | 2013 |
Role of nuclear receptor on regulation of BDNF and neuroinflammation in hippocampus of β-amyloid animal model of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Brain-Derived Neurotrophic Factor; Cognition Diso | 2014 |
Modulation of the Nitrergic Pathway via Activation of PPAR-γ Contributes to the Neuroprotective Effect of Pioglitazone Against Streptozotocin-Induced Memory Dysfunction.
Topics: Animals; Antioxidants; Apoptosis; Caspase 3; Interleukin-6; Male; Memory Disorders; Neuroprotective | 2015 |
Pioglitazone and exenatide enhance cognition and downregulate hippocampal beta amyloid oligomer and microglia expression in insulin-resistant rats.
Topics: Amyloid beta-Peptides; Animals; Cognition; Down-Regulation; Drug Therapy, Combination; Exenatide; Fr | 2016 |
Exploring mechanism of pioglitazone-induced memory restorative effect in experimental dementia.
Topics: Acetylcholinesterase; Animals; Blood Glucose; Brain; Dementia; Disease Models, Animal; Glutathione; | 2009 |
Effect of pioglitazone on insulin resistance in fructose-drinking rats correlates with AGEs/RAGE inhibition and block of NADPH oxidase and NF kappa B activation.
Topics: Animals; Brain; Drinking; Fructose; Gene Expression Regulation, Enzymologic; Glycation End Products, | 2010 |
Suppression of nitric oxide synthesis by L-NAME reverses the beneficial effects of pioglitazone on scopolamine-induced memory impairment in mice.
Topics: Animals; Drug Interactions; Maze Learning; Memory Disorders; Memory, Short-Term; Mice; Motor Activit | 2011 |
Lithium, phenserine, memantine and pioglitazone reverse memory deficit and restore phospho-GSK3β decreased in hippocampus in intracerebroventricular streptozotocin induced memory deficit model.
Topics: Animals; Conditioning, Classical; Disease Models, Animal; Enzyme Inhibitors; Glycogen Synthase Kinas | 2011 |
PPARγ agonist pioglitazone improves scopolamine-induced memory impairment in mice.
Topics: Administration, Oral; Alzheimer Disease; Animals; Avoidance Learning; Cerebral Cortex; Disease Model | 2012 |
Involvement of NMDA receptors in the beneficial effects of pioglitazone on scopolamine-induced memory impairment in mice.
Topics: Animals; Avoidance Learning; Dizocilpine Maleate; Excitatory Amino Acid Antagonists; Hypoglycemic Ag | 2012 |
Improvement in long term and visuo-spatial memory following chronic pioglitazone in mouse model of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Blood Glucose; Body Weight; Disease Models, Animal; Male; Maze Learning; | 2012 |
PPARγ agonist pioglitazone reverses memory impairment and biochemical changes in a mouse model of type 2 diabetes mellitus.
Topics: Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Animals; Aspartic Acid Endopeptidases; | 2012 |
Involvement of nitric oxide in pioglitazone memory improvement in morphine-induced memory impaired mice.
Topics: Animals; Avoidance Learning; Dose-Response Relationship, Drug; Fear; Male; Maze Learning; Memory Dis | 2012 |
Cerebral antioxidant enzyme increase associated with learning deficit in type 2 diabetes rats.
Topics: Adiponectin; Animals; Antioxidants; Brain; Cerebral Cortex; Conditioning, Operant; Corpus Striatum; | 2012 |
Participation of antioxidant and cholinergic system in protective effect of naringenin against type-2 diabetes-induced memory dysfunction in rats.
Topics: Animals; Antioxidants; Blood Glucose; Body Weight; Cholinesterase Inhibitors; Cholinesterases; Diabe | 2012 |
Chronic administration of pioglitazone attenuates intracerebroventricular streptozotocin induced-memory impairment in rats.
Topics: Administration, Oral; Aging; Animals; Antibiotics, Antineoplastic; Brain Chemistry; Cognition; Demen | 2006 |